Intelligent care provider Viz.ai has secured the US Food and Drug Administration (FDA) 510(k) clearance for an automated RV/LV ratio analysis algorithm.
The algorithm is the latest addition to the Viz PE solution, which measures the heart’s ventricles’ diameters to calculate the ratio of the maximal RV diameter to the RV diameter of the left ventricle (LV).
The automation of the patient risk signal will enable the care teams to respond more quickly than before.
The firm said pulmonary embolism (PE) patients need quick multidisciplinary communication for risk assessment and decision-making during diagnosis and care coordination.
Viz PE, which was introduced in November 2021, employs deep learning to quickly diagnose probable central and segmental pulmonary emboli.
The method now incorporates an automatic evaluation of potential right ventricle dilatation thanks to the incorporation of the RV/LV algorithm.
The information is rapidly delivered to the entire care team on the Viz PE Solution irrespective of the location of the patient, said the firm.
It enables care teams to further ensure that the right clinical choice is made at the right time to ensure speedy and appropriate care.
The FDA-cleared RV/LV ratio algorithm has been shown through clinical validation to enhance patient outcomes, access to care, and time efficiency across more than 1,200 health systems in the US and EMEA.
Viz.ai chief clinical officer Jayme Strauss said: “With AI-powered enhanced image interpretation that dramatically improves the quality and speed of mobile image viewing – and caregiver communication – Viz PE already helps identify suspected pulmonary embolisms in under two minutes.
“The addition of the RV/LV algorithm is expected to further aid care teams to quickly make the right clinical decision for their patients, improving outcomes and saving lives.”
In July this year, the company received 510(k) approval from the US FDA for its Viz Subdural (SDH).
